Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Skip to main content


George Tofaris graduated from the combined MB/PhD programme of Cambridge University in 2003. He completed his general medical training at the National Hospital for Neurology, Hammersmith, Royal Brompton and Royal Free hospitals in London in 2006. He worked for a year at the Neurology Department of the Austin hospital, an affiliate of Melbourne University. He was appointed Clinical Lecturer at Oxford in 2007 and completed his training in Clinical Neurology in 2011. Between 2008-09, he was awarded a Lefler fellowship from Harvard Medical School for advanced studies in neurodegenerative diseases. In 2012, he was awarded a Wellcome Trust Intermediate Clinical Fellowship and the Wellcome-Beit Prize to further his research and after a short visit at the Brigham and Women's Hospital in Boston, he established his research group at Oxford. He heads the EU IMI Consortium IMPRiND which aims to delineate new mechanisms that are relevant to the progression of pathology in Parkinson's and Alzheimer's disease. He is a Medical Research Fellow at Corpus Christi and previously held a Todd-Bird Junior Research Fellowship in Medicine at New College. He was the recipient of the biennial Cornelli Prize for research in Parkinson's disease and the Junior Investigator Award from the International Movement Disorder Society. As a clinically active Consultant Neurologist at the John Radcliffe hospital, he covers acute as well as general outpatient neurology and leads regional specialist clinics in Movement and Neurogenetic Disorders.

George Tofaris


Associate Professor and Honorary Consultant Neurologist

Molecular mechanisms of neurodegeneration

Research Summary

My research aim is to delineate cellular pathways in protein quality control that could inform the development of targeted therapies in neurodegenerative and neurogenetic disorders. To this end, my group uses forward genetics, proteomics and transcriptomics in models of increasing cellular complexity, including patient-derived induced pluripotent stem cells (iPSC).

Of particular interest to my group is the study of the ubiquitin pathway. It is now well established that transport of proteins or organelles to lysosomes and their subsequent degradation is especially relevant to Parkinson’s disease. An important signalling cascade in this pathway is the conjugation of a ubiquitin chain to protein-substrates or organelles such as mitochondria.  

We first demonstrated that α-synuclein is ubiquitinated in Lewy bodies and subsequently identified NEDD4 as a critical E3 in α-synuclein trafficking and toxicity. More recently we showed that in human brain, the expression of the deubiquitinase USP8 is increased in dopaminergic neurons with Lewy bodies, opposing α-synuclein clearance and increasing its toxicity in the Drosophila model.  Because the cellular accumulation of α-synuclein is causatively linked to neurodegeneration, our findings suggest novel mechanistic insights into the pathogenesis of Parkinson's and related diseases, which are the focus of current studies.

We are also interested in the role of mitochondrial dysfunction in  hereditary forms of neurodegeneration and the study of circulating exosomes as potential markers for Parkinson's disease stratification.